Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Trigeminal Neuralgia Treatment Pipeline Review H2 2016

Monday, October 10, 2016 5:47
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Trigeminal Neuralgia – Pipeline Review, H2 2016’, provides an overview of the Trigeminal Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects.

Complete report details @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia 
- The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects 
- The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia

Request a sample report @

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 
Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Global Markets Direct Report Coverage 6 
Trigeminal Neuralgia Overview 7 
Therapeutics Development 8 
Pipeline Products for Trigeminal Neuralgia – Overview 8 
Pipeline Products for Trigeminal Neuralgia – Comparative Analysis 9 
Trigeminal Neuralgia – Therapeutics under Development by Companies 10 
Trigeminal Neuralgia – Therapeutics under Investigation by Universities/Institutes 11 
Trigeminal Neuralgia – Pipeline Products Glance 12 
Clinical Stage Products 12 
Early Stage Products 13 
Unknown Stage Products 14 
Trigeminal Neuralgia – Products under Development by Companies 15 
Trigeminal Neuralgia – Products under Investigation by Universities/Institutes 16 
Trigeminal Neuralgia – Companies Involved in Therapeutics Development 17 
Allergan Plc 17 
Biogen Inc 18 
KPI Therapeutics, Inc. 19 
Merz Pharma GmbH & Co. KgaA 20 
Trigemina, Inc. 21 
Trigeminal Neuralgia – Therapeutics Assessment 22 
Assessment by Monotherapy Products 22 
Assessment by Combination Products 23 
Assessment by Target 24 
Assessment by Mechanism of Action 26 
Assessment by Route of Administration 28 
Assessment by Molecule Type 30 
Drug Profiles 32 
(clonidine hydrochloride + naltrexone hydrochloride) – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
incobotulinumtoxin A – Drug Profile 33 
Product Description 33 
Mechanism Of Action 33 
R&D Progress 33 
NeuroRelease TN – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
onabotulinumtoxin A – Drug Profile 38 
Product Description 38 
Mechanism Of Action 38 
R&D Progress 38 
oxytocin – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
raxatrigine hydrochloride – Drug Profile 45 
Product Description 45 
Mechanism Of Action 45 
R&D Progress 45 
Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia – Drug Profile 48 
Product Description 48 
Mechanism Of Action 48 
R&D Progress 48 
U-2902 – Drug Profile 49 
Product Description 49 
Mechanism Of Action 49 
R&D Progress 49 
Trigeminal Neuralgia – Dormant Projects 51 
Trigeminal Neuralgia – Product Development Milestones 52 
Featured News & Press Releases 52 
Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch 52 
Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs 53 
Mar 03, 2016: PixarBio’s Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016 53 
Nov 30, 2015: PixarBio’s Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY 54 
Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia 54 
Sep 23, 2014: Convergence Pharmaceuticals’ Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy 55 
Jun 16, 2014: Convergence Pharmaceuticals’ Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study 55 
Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 56 
Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study 57 
Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802 57 
Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia 58 
Appendix 59 
Methodology 59 
Coverage 59 
Secondary Research 59 
Primary Research 59 
Expert Panel Validation 59 
Contact Us 59 
Disclaimer 60

List of Tables 
Number of Products under Development for Trigeminal Neuralgia, H2 2016 8 
Number of Products under Development for Trigeminal Neuralgia – Comparative Analysis, H2 2016 9 
Number of Products under Development by Companies, H2 2016 10 
Number of Products under Investigation by Universities/Institutes, H2 2016 11 
Comparative Analysis by Clinical Stage Development, H2 2016 12 
Comparative Analysis by Early Stage Development, H2 2016 13 
Comparative Analysis by Unknown Stage Development, H2 2016 14 
Products under Development by Companies, H2 2016 15 
Products under Investigation by Universities/Institutes, H2 2016 16 
Trigeminal Neuralgia – Pipeline by Allergan Plc, H2 2016 17 
Trigeminal Neuralgia – Pipeline by Biogen Inc, H2 2016 18 
Trigeminal Neuralgia – Pipeline by KPI Therapeutics, Inc., H2 2016 19 
Trigeminal Neuralgia – Pipeline by Merz Pharma GmbH & Co. KgaA, H2 2016 20 
Trigeminal Neuralgia – Pipeline by Trigemina, Inc., H2 2016 21 
Assessment by Monotherapy Products, H2 2016 22 
Assessment by Combination Products, H2 2016 23 
Number of Products by Stage and Target, H2 2016 25 
Number of Products by Stage and Mechanism of Action, H2 2016 27 
Number of Products by Stage and Route of Administration, H2 2016 29 
Number of Products by Stage and Molecule Type, H2 2016 31 
Trigeminal Neuralgia – Dormant Projects, H2 2016 51

Get this report @

Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.